Skip to main content

Table 2 Clinical features of SSc patients.

From: The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy

Patients Age Sex SSc type Early/Late Duration (years) MRSS
N900 43 F     
N901 43 F     
N1003 26 M     
N1016 35 F     
S902 54 F lcSSc Early* 1 12
S903 39 F dcSSc Late 5 19
S904 33 F dcSSc Late 9 N/A
S1004 27 F dcSSc Late 10 26
S1066 21 M dcSSc Early 2 15
S1156 48 F SSc/PM Early 1 20
S1302 51 F lcSSc Early 2 4
  1. *early = < 2 years from first non-Raynaud symptom at the time of skin biopsy. Fibroblasts from N900-1016 and S902-1004 were used for real-time qPCR analysis. Fibroblasts from S1004-1302 were used for Western blot analysis. MRSS, Modified Rodnan skin score; SSc, systemic sclerosis.